332 related articles for article (PubMed ID: 17183620)
1. Summarizing disease features over time: II. Variability measures of SLEDAI-2K.
Ibañez D; Gladman D; Urowitz M
J Rheumatol; 2007 Feb; 34(2):336-40. PubMed ID: 17183620
[TBL] [Abstract][Full Text] [Related]
2. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE.
Ibañez D; Gladman DD; Urowitz MB
J Rheumatol; 2005 May; 32(5):824-7. PubMed ID: 15868616
[TBL] [Abstract][Full Text] [Related]
3. Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus.
Ibañez D; Urowitz MB; Gladman DD
J Rheumatol; 2003 Sep; 30(9):1977-82. PubMed ID: 12966601
[TBL] [Abstract][Full Text] [Related]
4. The effect of menopause on disease activity in systemic lupus erythematosus.
Urowitz MB; Ibañez D; Jerome D; Gladman DD
J Rheumatol; 2006 Nov; 33(11):2192-8. PubMed ID: 16981295
[TBL] [Abstract][Full Text] [Related]
5. Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity.
Cook RJ; Gladman DD; Pericak D; Urowitz MB
J Rheumatol; 2000 Aug; 27(8):1892-5. PubMed ID: 10955329
[TBL] [Abstract][Full Text] [Related]
6. Systemic lupus erythematosus disease activity index 2000.
Gladman DD; Ibañez D; Urowitz MB
J Rheumatol; 2002 Feb; 29(2):288-91. PubMed ID: 11838846
[TBL] [Abstract][Full Text] [Related]
7. Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality.
Becker-Merok A; Nossent HC
J Rheumatol; 2006 Aug; 33(8):1570-7. PubMed ID: 16845708
[TBL] [Abstract][Full Text] [Related]
8. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus.
Brunner HI; Gladman DD; Ibañez D; Urowitz MD; Silverman ED
Arthritis Rheum; 2008 Feb; 58(2):556-62. PubMed ID: 18240232
[TBL] [Abstract][Full Text] [Related]
9. The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus.
Uribe AG; Vilá LM; McGwin G; Sanchez ML; Reveille JD; Alarcón GS
J Rheumatol; 2004 Oct; 31(10):1934-40. PubMed ID: 15468356
[TBL] [Abstract][Full Text] [Related]
10. High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus.
Nived O; Jönsen A; Bengtsson AA; Bengtsson C; Sturfelt G
J Rheumatol; 2002 Jul; 29(7):1398-400. PubMed ID: 12136895
[TBL] [Abstract][Full Text] [Related]
11. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study.
Mok CC; Ho LY; Cheung MY; Yu KL; To CH
Scand J Rheumatol; 2009; 38(2):121-7. PubMed ID: 18991189
[TBL] [Abstract][Full Text] [Related]
12. European Consensus Lupus Activity Measurement is sensitive to change in disease activity in childhood-onset systemic lupus erythematosus.
Brunner HI; Silverman ED; Bombardier C; Feldman BM
Arthritis Rheum; 2003 Jun; 49(3):335-41. PubMed ID: 12794788
[TBL] [Abstract][Full Text] [Related]
13. Cigarette smoking and cutaneous damage in systemic lupus erythematosus.
Turchin I; Bernatsky S; Clarke AE; St-Pierre Y; Pineau CA
J Rheumatol; 2009 Dec; 36(12):2691-3. PubMed ID: 19884279
[TBL] [Abstract][Full Text] [Related]
14. Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus.
Tisseverasinghe A; Lim S; Greenwood C; Urowitz M; Gladman D; Fortin PR
Arthritis Rheum; 2006 Jul; 54(7):2211-9. PubMed ID: 16802357
[TBL] [Abstract][Full Text] [Related]
15. Disease activity, damage and survival in Mexican patients with acute severe systemic lupus erythematosus.
Zonana-Nacach A; Yañez P; Jiménez-Balderas FJ; Camargo-Coronel A
Lupus; 2007; 16(12):997-1000. PubMed ID: 18042596
[TBL] [Abstract][Full Text] [Related]
16. SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation.
Touma Z; Urowitz MB; Ibañez D; Gladman DD
Lupus; 2011 Jan; 20(1):67-70. PubMed ID: 21233149
[TBL] [Abstract][Full Text] [Related]
17. Greater accrual damage in late-onset systemic lupus erythematosus: a long-term follow-up study.
Appenzeller S; Pereira DA; Costallat LT
Lupus; 2008 Nov; 17(11):1023-8. PubMed ID: 18852227
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life in portuguese SLE patients: an outcome measure independent of disease activity and cumulative damage.
Duarte C; Abreu P; Couto M; Vaz C; Malcata A; Inês L
Acta Reumatol Port; 2010; 35(1):30-5. PubMed ID: 20518146
[TBL] [Abstract][Full Text] [Related]
19. Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality.
Abu-Shakra M; Urowitz MB; Gladman DD; Gough J
J Rheumatol; 1995 Jul; 22(7):1265-70. PubMed ID: 7562756
[TBL] [Abstract][Full Text] [Related]
20. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.
Petri M; Stohl W; Chatham W; McCune WJ; Chevrier M; Ryel J; Recta V; Zhong J; Freimuth W
Arthritis Rheum; 2008 Aug; 58(8):2453-9. PubMed ID: 18668552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
